EASL 2016 Comp Review



About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016). This program consists of four components: (1) CME Internet Symposium: EASL 2016 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) Rapid-Fire Review of EASL 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From EASL 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C therapy presented at EASL 2016. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

All online components of the program will be accessible at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2016 and it is not sanctioned by the organizers of EASL 2016.

Back to Top  

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2016

  • Employ the current treatment paradigms for CHC, including the studies and data presented at EASL 2016 to improve patient care

  • Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at EASL 2016 to decide on appropriate planning of therapy for patients with CHC

Release Date: April 25, 2016

Expiration Date: April 25, 2017

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top 


Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California

Jürgen Rockstroh, MD 
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

Doug Dieterich, MD

  • Consulting Fees: Gilead, BMS, AbbVie, Janssen
  • Fees for Non-CME/CE Services: Gilead, BMS, AbbVie, Janssen
  • Contracted Research: Gilead, BMS, AbbVie, Janssen

Paul Kwo, MD

  • Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
  • Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck,Conatus
  • Other (DSMB): Inovio

Paul Pockros, MD

  • Consulting Fees: Gilead, BMS, Merck, Abbvie
  • Fees for Non-CME/CE Services: Gilead, Merck, Abbvie, BMS
  • Contracted Research: Gilead, BMS, Merck, Genfit, Intercept, Medicinova, RMS, Janssen (To Scripps Health)

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck
  • Contracted Research: Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP and Jan Shultz, RN, MSN, CHCP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Back to Top  

Disclosure of Unlableled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top  

Poster/Presentation Listing

EASL 2016_Poster_LBO8 Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Mono-infection The HEPNET Acute HCV IV Study 
EASL 2016_Poster_PS104 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the TRIO Network
EASL-2016_Poster_Video_GS11_v2.jpg High Efficacy of ABT-493 and ABT-530 in HCV Genotype 1 Infected Patients Who Have Failed Direct-Acting Antiviral-Containing Regimens: The MAGELLAN-I Study/High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-infected Patients, Including Those Previously Treated with Direct-Acting Antivirals
EASL-2016_Poster_Video_SAT134-269.jpg Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network/
Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

C-SWIFT Retreatment Final Results: Highly Successful Retreatment of GT1-infected Patients with 12 Weeks of Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin After Failure of Short-Duration All-Oral Therapy/
C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir (EBR/GZR) in Subjects with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders

EASL-2016_Poster_Video_SAT138.jpg Short Duration Treatment with Sofosbuvir/Velpatasvir Plus GS-9857 in Treatment-Naïve Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
EASL-2016_Poster_Video_PS098-LB01_v2.jpg High SVR Rates with ABT-493 + ABT-530 Co-administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection/100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naive Genotype 3-infected Patients with Cirrhosis

Back to Top


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    


This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EASL 2016 and it is not sanctioned by the organizers of EASL 2016.

This activity is supported by an independent educational grant from Merck & Co.


Prepare to print

Share this page:

Get link code to this page                     

Back to Top